Category: Active Surveillance

The brain makes upward of 35,000 decisions a day, and few weigh as heavily as choosing a prostate cancer treatment. When a biopsy hints at a riskier cancer, genomic testing of the tissue can settle the question. A reassuring result gives men real confidence in Active Surveillance or focal therapy, and new 2026 research shows what a high score can warn about. keep reading

Harrison Ford traded meat and dairy for vegetables and fruit, and at 84 he has never been diagnosed with prostate cancer. One man is not proof, but the research is piling up. Studies of men on Active Surveillance now link plant-based eating to a lower chance of prostate cancer turning more aggressive over time, which could delay the need for treatment. keep reading

Is every prostate cancer a death threat? Many men assume so the moment they hear the word cancer. Yet experts now say grade 1 disease, the lowest grade, rarely causes trouble and may not even deserve the label. Rushing to surgery or radiation for it can bring lasting urinary, sexual, or bowel problems without adding real benefit. keep reading

For years, men with low-risk prostate cancer had two options and nothing in between: remove or irradiate the whole gland, or leave it alone and watch. About half who chose watching later quit, and most of them had no evidence their cancer had changed at all. Focal laser ablation closes that gap, and it changes the calculation entirely. keep reading

Nearly every man treated for low-risk prostate cancer survives it. That shifts the real question from whether treatment works to what life looks like once it is over. A five-year study followed 866 men and asked them, year after year, about leaking, bowel habits and sexual function. Focal therapy held up best across almost every measure. keep reading

Roughly 60% of men with low-risk prostate cancer start on Active Surveillance, and half walk away within five years, usually because PSA keeps climbing. A new trial asked whether two everyday supplements could steady those numbers. The findings were striking enough to publish, though the researchers stop well short of calling them a recommendation. keep reading

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

In a murder mystery, the killer is often hiding in plain sight. The same can happen with prostate cancer. In 10-15% of cases that appear low risk, hidden aggressive disease is waiting for an unexpected twist. A deeper diagnostic workup—mpMRI, genomic analysis, and other tools—can reveal the true nature of the disease before a treatment plan is locked in. keep reading

Focal therapy gives men with localized prostate cancer an appealing option—effective control with fewer side effects. Discover who qualifies for focal treatment, how it compares to radical approaches and Active Surveillance, and why specialized diagnosis is essential. keep reading

Deciding on Active Surveillance for prostate cancer isn’t always straightforward. Adding genomic testing to standard factors like PSA, MRI, and biopsy can reveal hidden risks and help ensure the safest, most personalized treatment path. keep reading